Commercial Strategy Expert | Immunology, Oncology, Hematology & Rare Disease | Leukemia & Lymphoma
Biopharmaceutical commercialization strategist with 22+ years across immunology, oncology, hematology and rare diseases, including 11 innovative therapeutic launches. My deepest specialization is leukemia, lymphoma and other lymphoproliferative disorders. I help biopharma, biotech and investor teams turn clinical evidence, unmet need and a shifting competitive landscape into launch-ready commercial strategy.
Most recently National Director, Hematology — Canada at BeOne Medicines, where I led the national hematology business and a team of nine Regional Managers. Today I advise global clients as Senior Consultant, Global Medical Strategy at Research Power Inc. (RPI).
Where I can help: • Launch and market-entry planning in immunology, oncology, hematology and rare diseases • Leukemia and lymphoma strategy: CLL, lymphoma and related lymphoproliferative disorders, including BTK inhibitors and fixed-duration vs. continuous therapy • Competitive intelligence, positioning and value-propositi
A working session for teams planning a launch or market entry in immunology, oncology, hematology or rare disease, with particular depth in leukemia and lymphoma. We pressure-test your positioning against the competitive landscape, map the reimbursement path (pCPA and provincial listing agreements), and sanity-check go-to-market, field-force sizing and forecast assumptions. Send background materials ahead of time to get the most from the hour.
A focused call on a specific question in immunology, oncology, hematology or rare disease: launch or market-entry planning, competitive positioning (e.g., BTK inhibitors and fixed-duration vs. continuous therapy in leukemia and lymphoma), pCPA/provincial access, or sales-force and forecast design. Share your question when booking so the time is spent on answers.
A working session for teams planning a launch or market entry in immunology, oncology, hematology or rare disease, with particular depth in leukemia and lymphoma. We pressure-test your positioning against the competitive landscape, map the reimbursement path (pCPA and provincial listing agreements), and sanity-check go-to-market, field-force sizing and forecast assumptions. Send background materials ahead of time to get the most from the hour.
A focused call on a specific question in immunology, oncology, hematology or rare disease: launch or market-entry planning, competitive positioning (e.g., BTK inhibitors and fixed-duration vs. continuous therapy in leukemia and lymphoma), pCPA/provincial access, or sales-force and forecast design. Share your question when booking so the time is spent on answers.